As a urinary biomarker, MCP-1 level has been demonstrated to increase in JSLE LN flares, to be a fair-good predictor of LN activity and to be higher in non-responders to therapy [44,45,48,50,54]. The gene discussed is CCL2; the disease is lobular neoplasia.